Le Lézard

Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces positive topline results from a U.S. Phase II, 24-week study for its subcutaneous (SQ) depot formulations of small molecule GLP-1 receptor ...

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...

Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after ...
The Manila Times

TECVAYLI® (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...
Finanznachrichten

Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...
Becker's ASC

Tennessee lawmakers weigh expanding optometrists’ scope of practice

The Tennessee General Assembly is considering companion bills that would allow optometrists to perform additional procedures. House Bill 1952 and Senate Bill 2076 would clarify that the practice ...